HIV感染青少年与成人的麻疹血清阳性率及疫苗应答:系统综述
该系统综述检索8个数据库至2017年9月26日,纳入30项研究。HIV感染青少年与成人麻疹血清阳性率中位数92%,与HIV未感染者无显著差异;血清阴性HIV感染成人接种含麻疹疫苗后血清阳性率0%至56%(中位数39%)。研究不支持对该人群额外接种含麻疹疫苗,支持WHO指南对易感无症状HIV感染成人接种麻疹疫苗。
要点
- HIV感染青少年与成人麻疹血清阳性率中位数92%,与HIV未感染者无显著差异。
- 血清阴性HIV感染成人接种含麻疹疫苗后血清阳性率0%至56%(中位数39%)。
- 研究不支持对HIV感染青少年与成人额外接种含麻疹疫苗。
核心结论
- 基于HIV感染与未感染青少年和成人麻疹血清阳性率相似且疫苗接种应答低,研究不支持对该人群额外接种含麻疹疫苗。
- 研究支持WHO指南对潜在易感、无症状HIV感染成人接种麻疹疫苗,对症状性HIV感染但非严重免疫抑制者可考虑接种。
研究设计与样本
- 系统综述,检索8个数据库至2017年9月26日,由2名评价员独立筛选,纳入30项符合标准的研究。
主要发现
- HIV感染青少年与成人麻疹血清阳性率中位数92%(27项研究),与HIV未感染者相比无显著差异(10项研究)。
- 6项评估血清阴性HIV感染成人含麻疹疫苗免疫原性的研究中,随访结束时麻疹血清阳性率为0%至56%(中位数39%)。
- HIV感染患者接种麻疹疫苗后未报告严重不良事件。
关键数值与推荐
- HIV感染青少年与成人麻疹血清阳性率中位数92%(27项研究)。
- 血清阴性HIV感染成人接种含麻疹疫苗后血清阳性率范围0%至56%,中位数39%(6项研究)。
临床怎么用
- 对潜在易感、无症状HIV感染成人接种麻疹疫苗。
- 对症状性HIV感染但非严重免疫抑制者可考虑接种麻疹疫苗。
- 对麻疹易感青少年和成人无论HIV状态可开展针对性疫苗接种以达关键接种阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization (WHO) recommends an additional dose of measles-containing vaccine (MCV) for human immunodeficiency virus (HIV)-infected children receiving highly active antiretroviral therapy following immune reconstitution. We conducted a systematic review to synthesize available evidence regarding measles seroprevalence and measles vaccine immunogenicity, efficacy, and safety in HIV-infected adolescents and adults to provide the evidence base for recommendations on the need for measles vaccination. METHODS: We conducted searches of 8 databases through 26 September 2017. Identified studies were screened independently by 2 reviewers. RESULTS: The search identified 30 studies meeting inclusion criteria. Across studies, measles seroprevalence among HIV-infected adolescents and adults was high (median, 92%; 27 studies), with no significant difference compared to HIV-uninfected participants (10 studies). In 6 studies that evaluated the immunogenicity of MCVs among seronegative HIV-infected adults, measles seropositivity at end of follow-up ranged from 0% to 56% (median, 39%). No severe adverse events were reported following measles vaccination in HIV-infected patients. CONCLUSIONS: Based on similar measles seroprevalence between HIV-infected and HIV-uninfected adolescents and adults, and the low response to vaccination, these studies do not support the need for an additional dose of MCV in HIV-infected adolescents and adults. These findings support WHO guidelines that measles vaccine be administered to potentially susceptible, asymptomatic HIV-infected adults, and may be considered for those with symptomatic HIV infection if not severely immunosuppressed. Measles-susceptible adolescents and adults, regardless of HIV status, may require targeted vaccination efforts to reach critical vaccination thresholds and achieve regional elimination goals.
引用
- Loevinsohn G, Rosman L, Moss WJ, et al. Measles Seroprevalence and Vaccine Responses in Human Immunodeficiency Virus-infected Adolescents and Adults: A Systematic Review. Clin Infect Dis. 2019. PMID: 30452621. doi:10.1093/cid/ciy980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。